The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP
about
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activationCharacterization of the myotubularin dual specificity phosphatase gene family from yeast to humanFibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathwaysFunctional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancersCharacterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocationThe oncogenic fusion protein-tyrosine kinase ZNF198/fibroblast growth factor receptor-1 has signaling function comparable with interleukin-6 cytokine receptorsZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1.ZNF198 stabilizes the LSD1-CoREST-HDAC1 complex on chromatin through its MYM-type zinc fingersPhosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.Receptor tyrosine kinase mutations in myeloid neoplasms.Characterization of the SUMO-binding activity of the myeloproliferative and mental retardation (MYM)-type zinc fingers in ZNF261 and ZNF198Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.Eosinophilia: secondary, clonal and idiopathic.Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Molecular diagnosis of myeloproliferative neoplasms.Fibroblast growth factors and their receptors in cancer.World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.Identification of four new translocations involving FGFR1 in myeloid disorders.Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
P2860
Q22254704-C53CB29E-739A-4BDD-A678-2A862528930CQ24291107-92657436-CD29-4BF2-B8A5-EAB25B007FE5Q24313350-A65D7DBE-8626-4791-B866-8F58A75ECA23Q24313675-6DB2A496-F8B8-49B0-9CEE-F43E7198EF83Q24548250-9B5506C2-8680-47CB-87E4-DEE077DEC27DQ26998955-3A5AED4F-742B-4339-8BF2-4D1D650A0C4AQ28144144-D05F28DF-163C-48E3-A923-E9137DDDD244Q28210567-9083E271-1897-4DE1-813D-22AD1C5E9320Q28609080-F6F1F134-D0AF-47D6-9393-33E10A803686Q33365634-2DAC3DCB-2C46-4A7C-BC87-C474FA4C84BAQ33370931-C8F4529A-8799-45EC-B6EF-FA4F3148869FQ34378275-195BF2CA-0809-439B-A38D-3A93DBA4DD51Q34655403-F26AA8A8-F936-48C7-B367-DC05EB26D8E0Q35227096-BB155265-ED4E-4D73-B615-26803759E1B2Q36182741-C3F0C0D7-27CC-46B7-8963-01A41C74E7CFQ36471689-72138DEE-268B-4642-8CB6-6361A9CC3514Q36513663-D714B504-F06D-4229-96C3-691C5F7FDA5CQ37379320-C9211EBC-E09C-46AD-9754-3AA18156CD16Q37542270-FA602EAE-A8DB-4108-9541-F8BDF5CC88C6Q37895306-10F5C398-52EE-43D0-8F7E-31500DA86863Q37901437-03E3409E-827F-4E04-A5CE-A476B69E90F4Q38038509-1B9D61D3-2E37-49C5-89E5-5D91005BCBB2Q38191834-225DB755-9F04-4330-B4D0-4F5BDC0A6694Q38316836-1A797D6E-71B2-4DDC-B6CB-57A595AD8D47Q40609712-BAA768C8-9B15-410E-98D8-B921F8ADC0AFQ43732967-FB51B2AC-47B4-403E-B5A5-84FCDBFF3490Q43825958-2E5143DD-A42A-4172-80DC-BC5649397E08Q46026437-8E865AA2-48EA-49C5-8348-003CCE32C702
P2860
The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@ast
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@en
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@nl
type
label
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@ast
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@en
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@nl
prefLabel
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@ast
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@en
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@nl
P2093
P356
P1476
The t(8;13)(p11;q11-12) rearra ...... or 1 gene to a novel gene RAMP
@en
P2093
M Abdul-Rauf
P304
P356
10.1093/HMG/7.4.637
P407
P577
1998-04-01T00:00:00Z